Trial Profile
An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs FB 825 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Fountain BioPharma; Oneness Biotech
- 20 Feb 2021 Status changed from active, no longer recruiting to completed.
- 22 Feb 2019 Planned End Date changed from 31 Dec 2018 to 10 Apr 2019.
- 28 Nov 2018 Status changed from recruiting to active, no longer recruiting.